MINIMAL RESIDUAL DISEASE MONITORING AND PREEMPTIVE IMMUNOTHERAPY IN MYELODYSPLASTIC SYNDROME AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
(Abstract release date: 05/19/16)
EHA Library. Mo X. 06/09/16; 132763; E1214
Dr. Xiao-Dong Mo
Contributions
Contributions
Abstract
Abstract: E1214
Type: Eposter Presentation
Background
Allogeneic hematopoietic stem cell transplantation (HSCT) is one of the most effective treatments for high-risk myelodysplastic syndromes (MDS). Although allogeneic HSCT has advanced significantly, post-transplant relapse remains an important cause of transplant failure. The presence of minimal residual disease (MRD) after HSCT can indicate impending relapse.
Aims
This study investigated the efficacy of MRD monitoring and MRD-directed preemptive immunotherapy in high-risk MDS patients who received allogeneic HSCT.
Methods
MRD assessment consisted of Wilms’ tumor gene 1 (WT1) detection with PCR and leukemia-associated immunophenotypic pattern examination with multiparameter flow cytometry (FCM).
Results
Post-HSCT, 31 patients were positive for WT1, and 8, for FCM; positivity for WT1 (18.6% vs. 6.1%, P = 0.040) or FCM (62.5% vs. 3.6%, P < 0.001) indicated a higher 2-year relapse rate. Twenty-one patients met our combined criteria for MRD, and the presence of MRD was associated with a higher 2-year relapse rate (27.3% vs. 4.5%, P = 0.003). Thirty-one patients showed positive results for preferentially expressed antigen of melanoma (PRAME) after HSCT, which indicated a higher 2-year relapse rate (19.3% vs. 6.2%, P = 0.035). In patients positive for both PRAME and MRD, the relapse rate was 60% despite preemptive immunotherapy. Multivariate analysis confirmed the association between the increased relapse rate and positivity for both PRAME and MRD (hazard ratio = 42.8, P = 0.001).
Conclusion
MRD monitoring predicted relapse in high-risk MDS post-HSCT patients, and PRAME- and MRD-positive patients did not benefit from preemptive immunotherapy.
Session topic: E-poster
Keyword(s): Minimal residual disease (MRD)
Type: Eposter Presentation
Background
Allogeneic hematopoietic stem cell transplantation (HSCT) is one of the most effective treatments for high-risk myelodysplastic syndromes (MDS). Although allogeneic HSCT has advanced significantly, post-transplant relapse remains an important cause of transplant failure. The presence of minimal residual disease (MRD) after HSCT can indicate impending relapse.
Aims
This study investigated the efficacy of MRD monitoring and MRD-directed preemptive immunotherapy in high-risk MDS patients who received allogeneic HSCT.
Methods
MRD assessment consisted of Wilms’ tumor gene 1 (WT1) detection with PCR and leukemia-associated immunophenotypic pattern examination with multiparameter flow cytometry (FCM).
Results
Post-HSCT, 31 patients were positive for WT1, and 8, for FCM; positivity for WT1 (18.6% vs. 6.1%, P = 0.040) or FCM (62.5% vs. 3.6%, P < 0.001) indicated a higher 2-year relapse rate. Twenty-one patients met our combined criteria for MRD, and the presence of MRD was associated with a higher 2-year relapse rate (27.3% vs. 4.5%, P = 0.003). Thirty-one patients showed positive results for preferentially expressed antigen of melanoma (PRAME) after HSCT, which indicated a higher 2-year relapse rate (19.3% vs. 6.2%, P = 0.035). In patients positive for both PRAME and MRD, the relapse rate was 60% despite preemptive immunotherapy. Multivariate analysis confirmed the association between the increased relapse rate and positivity for both PRAME and MRD (hazard ratio = 42.8, P = 0.001).
Conclusion
MRD monitoring predicted relapse in high-risk MDS post-HSCT patients, and PRAME- and MRD-positive patients did not benefit from preemptive immunotherapy.
Session topic: E-poster
Keyword(s): Minimal residual disease (MRD)
Abstract: E1214
Type: Eposter Presentation
Background
Allogeneic hematopoietic stem cell transplantation (HSCT) is one of the most effective treatments for high-risk myelodysplastic syndromes (MDS). Although allogeneic HSCT has advanced significantly, post-transplant relapse remains an important cause of transplant failure. The presence of minimal residual disease (MRD) after HSCT can indicate impending relapse.
Aims
This study investigated the efficacy of MRD monitoring and MRD-directed preemptive immunotherapy in high-risk MDS patients who received allogeneic HSCT.
Methods
MRD assessment consisted of Wilms’ tumor gene 1 (WT1) detection with PCR and leukemia-associated immunophenotypic pattern examination with multiparameter flow cytometry (FCM).
Results
Post-HSCT, 31 patients were positive for WT1, and 8, for FCM; positivity for WT1 (18.6% vs. 6.1%, P = 0.040) or FCM (62.5% vs. 3.6%, P < 0.001) indicated a higher 2-year relapse rate. Twenty-one patients met our combined criteria for MRD, and the presence of MRD was associated with a higher 2-year relapse rate (27.3% vs. 4.5%, P = 0.003). Thirty-one patients showed positive results for preferentially expressed antigen of melanoma (PRAME) after HSCT, which indicated a higher 2-year relapse rate (19.3% vs. 6.2%, P = 0.035). In patients positive for both PRAME and MRD, the relapse rate was 60% despite preemptive immunotherapy. Multivariate analysis confirmed the association between the increased relapse rate and positivity for both PRAME and MRD (hazard ratio = 42.8, P = 0.001).
Conclusion
MRD monitoring predicted relapse in high-risk MDS post-HSCT patients, and PRAME- and MRD-positive patients did not benefit from preemptive immunotherapy.
Session topic: E-poster
Keyword(s): Minimal residual disease (MRD)
Type: Eposter Presentation
Background
Allogeneic hematopoietic stem cell transplantation (HSCT) is one of the most effective treatments for high-risk myelodysplastic syndromes (MDS). Although allogeneic HSCT has advanced significantly, post-transplant relapse remains an important cause of transplant failure. The presence of minimal residual disease (MRD) after HSCT can indicate impending relapse.
Aims
This study investigated the efficacy of MRD monitoring and MRD-directed preemptive immunotherapy in high-risk MDS patients who received allogeneic HSCT.
Methods
MRD assessment consisted of Wilms’ tumor gene 1 (WT1) detection with PCR and leukemia-associated immunophenotypic pattern examination with multiparameter flow cytometry (FCM).
Results
Post-HSCT, 31 patients were positive for WT1, and 8, for FCM; positivity for WT1 (18.6% vs. 6.1%, P = 0.040) or FCM (62.5% vs. 3.6%, P < 0.001) indicated a higher 2-year relapse rate. Twenty-one patients met our combined criteria for MRD, and the presence of MRD was associated with a higher 2-year relapse rate (27.3% vs. 4.5%, P = 0.003). Thirty-one patients showed positive results for preferentially expressed antigen of melanoma (PRAME) after HSCT, which indicated a higher 2-year relapse rate (19.3% vs. 6.2%, P = 0.035). In patients positive for both PRAME and MRD, the relapse rate was 60% despite preemptive immunotherapy. Multivariate analysis confirmed the association between the increased relapse rate and positivity for both PRAME and MRD (hazard ratio = 42.8, P = 0.001).
Conclusion
MRD monitoring predicted relapse in high-risk MDS post-HSCT patients, and PRAME- and MRD-positive patients did not benefit from preemptive immunotherapy.
Session topic: E-poster
Keyword(s): Minimal residual disease (MRD)
{{ help_message }}
{{filter}}